- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARIâ"¢ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the presentation of an abstract from its XYNGARIâ"¢ (also known as DMT310) Phase 3 Spongilla Treatment of Acne Research clinical trial (STAR-1) will ...